Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating activities
Net income (loss)	$ (75,144)	$ (36,317)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	8,320	1,418
Bargain purchase gain in connection with reverse merger	0	(16,355)
Depreciation and amortization of property and equipment	3,195	3,262
Asset impairment	91	0
Non-cash operating lease expense	741	663
Amortization of finance lease right-of-use assets	52	35
Amortization and accretion of premiums/discounts on held-to-maturity investments	(2,419)	(105)
Contingent value rights liability	522	0
Changes in assets and liabilities:
Prepaid expenses and other current assets	(327)	326
Other assets	(211)	(764)
Accounts payable	(77)	667
Accrued expenses and other liabilities	(2,773)	(3,574)
Operating lease liabilities	(2,573)	(678)
Net cash used in operating activities	(70,603)	(51,422)
Investing activities
Purchases of property and equipment	(808)	(321)
Cash and restricted cash acquired from reverse merger transaction	0	22,243
Reverse merger transaction costs paid	0	(1,285)
Purchases of held-to-maturity investments	(198,453)	0
Proceeds from maturities of held-to-maturity investments	74,000	5,000
Net cash (used in) provided by investing activities	(125,261)	25,637
Financing activities
Proceeds from pre-closing financing, net of offering costs paid	0	92,343
Offering costs in connection with pre-closing financing	(4,287)	0
Transaction costs related to reverse merger	(2,855)	0
Proceeds from the issuance of common stock upon exercise of options	1,676	168
Proceeds from private financing, net of offering costs paid	189,589	0
Principal payments on finance leases	(52)	(29)
Net cash provided by financing activities	184,071	92,482
Net increase (decrease) in cash, cash equivalents and restricted cash	(11,793)	66,697
Cash, cash equivalents and restricted cash at beginning of period	148,718	82,021
Cash, cash equivalents and restricted cash at end of period	136,925	148,718
Supplemental disclosure of non-cash investing and financing activities:
Additions to operating lease right of use assets from new operating lease liabilities	60	0
Property and equipment included in accounts payable and accrued expenses	726	0
Additions to finance lease right of use assets from new finance lease liabilities	25	46
Offering costs related to private offering, included in accounts payable and accrued expenses	90	0
Operating lease liabilities assumed in connection with the reverse merger	0	10,940
Contingent consideration liability assumed in the reverse merger	0	1,287
Other liabilities assumed in the reverse merger	0	10,110
Assets acquired in the reverse merger including $53.9 million in ST investments and $0.8 million in other monetary assets	0	54,661
Issuance of common stock and pre-funded warrants to former stockholders of Neoleukin Therapeutics, Inc. in connection with the reverse merger	0	38,212
Offering costs in connection with pre-closing financing included in accounts payable and accrued expenses	0	4,287
Transaction costs related to reverse merger included in accounts payable and accrued expenses	0	2,855
Conversion of preferred stock into common stock in connection with reverse merger	0	244,366
Supplemental cash flow information:
Cash paid for interest	$ 12	$ 12